Table 1.
Patient characteristics
| All (n=70) |
TNFi (n=30) |
IL17 (n=20) |
MTX (n=20) |
p-value | |
|---|---|---|---|---|---|
| Female | 39 (55.71) | 17 (56.67) | 12 (60.00) | 10 (50.00) | 0.811 |
| Age, years | 51.50 (45.23-61.23) | 49.25 (41.83-59.12) | 50.15 (45.17-61.95) | 56.80 (51.35-62.38) | 0.133 |
| Disease duration, years | 4.00 (1.58-10.00) | 3.67 (1.56-8.31) | 7.75 (1.65-14.25) | 3.13 (1.44-10.75) | 0.645 |
| Treatment | |||||
| Previous bDMARD | |||||
| Bio-naïve | 40 (57.14) | 20 (66.67) | 2 (10.00) | 18 (90.00) | < 0.001 |
| 1 | 15 (21.43) | 7 (23.33) | 6 (30.00) | 2 (10.00) | |
| 2 | 8 (11.43) | 2 (6.67) | 6 (30.00) | 0 (0.00) | |
| 3 | 3 (4.29) | 0 (0.00) | 3 (15.00) | 0 (0.00) | |
| 4 | 3 (4.29) | 1 (3.33) | 2 (10.00) | 0 (0.00) | |
| 5 | 1 (1.43) | 0 (0.00) | 1 (5.00) | 0 (0.00) | |
| Concomitant csDMARD | 22 (31.43) | 13 (43.33) | 9 (45.00) | 0 (0.00) | 0.016 |
| Clinical phenotypes | |||||
| DAPSA | 29.20 (21.80-39.90) | 27.90 (21.85-39.73) | 36.70 (26.00-47.45) | 27.55 (20.50-36.83) | 0.187 |
| PASI | 1.20 (0.00-3.30) | 1.50 (0.30-3.40) | 0.08 (0.00-2.83) | 0.95 (0.00-2.93) | 0.570 |
| PsA without psoriasis | 22 (31.43) | 8 (26.67) | 8 (40.00) | 6 (30.00) | 0.469 |
| Dactylitis | 16 (22.86) | 6 (20.00) | 6 (30.00) | 4 (20.00) | 0.869 |
| Enthesitis | 54 (77.14) | 24 (80.00) | 16 (80.00) | 14 (70.00) | 0.553 |
| Nail psoriasis | 43 (61.43) | 19 (63.33) | 10 (50.00) | 14 (70.00) | 0.383 |
| Immune cellular frequency | |||||
| CD8+ T cells, % | 19.98 (15.12-25.27) | 21.02 (18.63-25.76) | 18.51 (13.14-23.44) | 17.70 (14.96-23.11) | 0.086 |
| Th1 cells, % | 1.79 (1.28-2.96) | 1.79 (1.50-3.43) | 2.25 (1.48-2.94) | 1.44 (1.05-2.47) | 0.239 |
| Th17 cells, % | 3.32 (2.40-4.61) | 3.25 (2.45-4.50) | 3.73 (3.09-5.03) | 2.81 (2.29-3.36) | 0.089 |
| nTregs, % | 1.21 (0.87-1.48) | 1.22 (0.98-1.56) | 1.13 (0.78-1.50) | 1.24 (0.82-1.44) | 0.773 |
| uamTregs, % | 1.13 (0.89-1.50) | 1.13 (0.95-1.42) | 1.23 (0.86-1.62) | 1.07 (0.79-1.56) | 0.942 |
| amTregs, % | 0.38 (0.22-0.57) | 0.36 (0.23-0.58) | 0.51 (0.21-0.63) | 0.36 (0.25-0.49) | 0.760 |
| Dendritic cells, % | 1.21 (0.76-1.82) | 1.30 (0.77-1.59) | 1.18 (0.79-1.86) | 1.10 (0.72-2.18) | 0.900 |
| NK cells, % | 7.42 (5.04-9.69) | 6.87 (5.16-9.18) | 5.80 (4.00-8.69) | 9.14 (6.07-11.41) | 0.186 |
| Monocytes, % | 3.79 (2.08-5.41) | 3.66 (2.03-4.85) | 3.50 (2.11-5.13) | 4.03 (3.41-8.13) | 0.352 |
Patient demographics and treatment characteristics were presented as medians with corresponding interquartile range (IQR) for continuous variables and number of patients with corresponding percentage for categorical variables. Immune cellular frequencies were given as the median percentage of the lymphocyte population with corresponding IQR
bDMARD biological Disease Modifying Anti-rheumatic Drug, csDMARD conventional synthetic Disease Modifying Anti-Rheumatic Drug, DAPSA Disease Activity for Psoriatic Arthritis, PASI Psoriasis Area and Severity Index, Th T helper, nTregs naïve T regulatory cells, uamTregs unactivated memory T regulatory cells, amTregs Activated Memory Tregs, NK cells Natural Killer cells